Research Pipeline

Since 1982, we’ve led the fight against PKD through the support of basic, translational, and clinical scientists; vital research funding; and patient education. Today, we’re encouraged by the significant strides we’re making to find treatments. We’ve gone from a single drug in clinical trials to an approved drug, tolvaptan, and more drugs in the pipeline today than ever before. Read on to learn more about the treatments for PKD currently being developed in the United States.